Top Markets
#1 Islamic Coin Islamic Coin +151.61%
#2 Black Phoenix Black Phoenix +35.36%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.36%
#4 Akedo Akedo +16.92%
#5 Fake World Assets Fake World Assets +15.77%
#6 Palladium Network Palladium Network +15.41%
#7 HOME HOME +12.57%
#8 clBTC clBTC +11.81%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.75%
#10 MarsCoin MarsCoin +10.60%
Coin of the day
Islamic Coin Islamic Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Arecor Therapeutics plc Arecor Therapeutics plc

Arecor Therapeutics plc

AREC
Rang in Aktien #39891
Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating... Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.
Aktienkurs
$0.80961743
Zuletzt synchronisiert: 2026-08-13
Marktkapitalisierung
$305.68K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-5.76%
Land
GB
Handel Arecor Therapeutics plc (AREC)

Kategorie

Healthcare
P/B-Verhältnis für Arecor Therapeutics plc (AREC)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Arecor Therapeutics plc beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Arecor Therapeutics plc von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE